Zoetis Inc. $ZTS Shares Acquired by Prospera Financial Services Inc

Prospera Financial Services Inc increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 8.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,313 shares of the company’s stock after purchasing an additional 1,545 shares during the quarter. Prospera Financial Services Inc’s holdings in Zoetis were worth $3,169,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ZTS. Nuveen LLC bought a new position in shares of Zoetis in the 1st quarter worth about $616,375,000. Mackenzie Financial Corp raised its stake in Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after acquiring an additional 1,782,110 shares during the period. Polen Capital Management LLC raised its stake in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Amundi lifted its holdings in Zoetis by 30.8% in the first quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after acquiring an additional 846,909 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd boosted its stake in Zoetis by 475.9% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after acquiring an additional 743,926 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.5%

NYSE:ZTS opened at $120.20 on Monday. The stock has a market cap of $52.97 billion, a price-to-earnings ratio of 20.69, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 1 year low of $117.26 and a 1 year high of $181.85. The business has a fifty day moving average of $144.21 and a 200-day moving average of $152.63.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is currently 33.67%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.